Crohn's: elan on hold, but rest of field is not
Vedolizumab is a monoclonal antibody being developed by Millennium Pharmaceuticals, Inc. for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1)
same mechanism as tysabri..
Published 14 May 2012
Takeda Pharmaceutical Company has announced that GEMINI II pivotal Phase III trial of vedolizumab in moderately to severely active Crohn's disease patients has met primary endpoints.
The trial evaluated vedolizumab in 1,115 Crohn's disease patients who have failed at least one conventional therapy, including TNFa antagonists.
Takeda General Medicine (Gastrointestinal and Genitourinary) vice president Asit Parikh said, "People living with moderately to severely active Crohn's disease currently have few treatment options to help them manage their disease."
Vedolizumab demonstrated statistically significant improvement in the primary endpoint of clinical remission compared to placebo, ininduction and maintenance phases of the trial.